Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease. (September 2021)

• Record Type: Journal Article
• Authors: Weber, Brittany; Liao, Katherine P.; DiCarli, Marcelo; Blankstein, Ron
• Is Part Of: Current opinion in cardiology. Volume 36:Number 5(2021)
• Publication Date: 2021-09
• Subjects: cardiac prevention -- psoriasis -- rheumatoid arthritis -- systemic inflammatory disease -- systemic lupus erythematosus; Cardiology -- Periodicals; Cardiology -- Periodicals; Heart Diseases -- Periodicals; Cardiology; Periodicals; 616.12
• DOI: 10.1097/HCO.0000000000000877
• Languages: English
• ISSNs: 0268-4705

Abstract

Abstract : Purpose of review: Patients with chronic inflammatory disease have an increased risk of cardiovascular disease. This article reviews the current evidence of cardiovascular prevention in three common systemic inflammatory disorders (SIDs): psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. Recent findings: General population cardiovascular risk assessment tools currently underestimate cardiovascular risk and disease-specific risk assessment tools are an area of active investigation. A disease-specific cardiovascular risk estimator has not been shown to more accurately predict risk compared with the current guidelines. Rheumatoid arthritis-specific risk estimators have been shown to better predict cardiovascular risk in some cohorts and not others. Systemic lupus erythematosus-specific scores have also been proposed and require further validation, whereas psoriasis is an open area of active investigation. The current role of universal prevention treatment with statin therapy in patients with SID remains unclear. Aggressive risk factor modification and control of disease activity are important interventions to reduce cardiovascular risk. Summary: A comprehensive approach that includes cardiovascular risk factor modification, control of systemic inflammation, and increased patient and physician awareness is needed in cardiovascular prevention of chronic inflammation. Clinical trials are currently underway to test whether disease-specific anti-inflammatory therapies will reduce cardiovascular risk.